RESEARCH
CROHN'S DISEASE AND ULCERATIVE COLITIS are inflammatory bowel diseases (IBD) that affect approximately 1 in 200 individuals in the United States. IBD can in part be hereditary, due to an overactive immune system, and pertain to factors related to the environment (i.e., smoking, medications, etc.). The chronic intestinal inflammation in IBD can result in significant symptoms like diarrhea, abdominal pain, weight loss, and eventually leading to complications that may require hospitalization and surgery. Though there have been advancements in IBD medical therapies, many patients do not tolerate or respond to current treatments and need other medical options.
Clinical drug trials provide novel medications that may be effective for Crohn’s disease and ulcerative colitis. We provide these therapies for our patients to provide additional treatment options. Dr. Taleban has significant experience directing Crohn’s disease and ulcerative colitis drug trials. If you meet the eligibility criteria for drug trials, he will work closely with you to help decide the most appropriate therapy.
Please contact Maggie Drury by email at medrury@arizona.edu or by phone at (520) 626-3021 if you are interested in learning more about one of our clinical drug trials.